المؤلفون: Manzano, José L., Martin Liberal, Juan, Fernández Morales, Luis A., Benítez, Gretel, Medina Martínez, Javier, Quindós, María, García Castaño, Almudena, Fernández, Ovidio, Simo, Rocío V., Majem, Margarita, Bellido, Lorena, Ayala de Miguel, Pablo, Campos Bonilla, Begoña, Espinosa, Enrique, Macías Cerrolaza, José A., Gil Arnaiz, Irene, Lorente, David, Rodriguez Lescure, Alvaro, Perez, Victor N., López Castro, Rafael, Gramaje, María G., Puértolas, Teresa, Rodriguez Moreno, Juan F., Espasa Font, Laia, Belaustegui Ferrández, Guillermo, Cerezuela Fuentes, Pablo

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Tractament adjuvant del càncer, Melanoma, Adjuvant treatment of cancer

الوصف: BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-V600 mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospective observational study, collected real-world data from 25 hospitals in Spain. Histologically confirmed and resected BRAF-mutated melanoma patients aged & GE;18 years who were previously treated with dabrafenib plus trametinib adjuvant therapy, were included. The primary objectives were treatment discontinuation rate and time to discontinuation. The secondary objectives included safety and efficacy. From October 2020 to March 2021, 65 patients were included. Dabrafenib and trametinib discontinuation rate due to treatment-related adverse events (TRAEs) of any grade was 9%. Other reasons for discontinuation included patients' decisions (6%), physician decisions (6%), unrelated adverse events (3%), disease progression (5%), and others (5%). The median time to treatment discontinuation was 9 months [95% confidence interval (CI), 5-11]. G3-4 TRAEs occurred in 21.5% of patients, the most common being pyrexia (3%), asthenia (3%), and diarrhoea (3%). Unscheduled hospitalisations and clinical tests occurred in 6 and 22% of patients, respectively. After 20-month median follow-up (95% CI, 18-22), 9% of patients had exitus due to disease progression, with a 12-month relapse-free survival and overall survival rates of 95.3% and 100%, respectively. Dabrafenib and trametinib adjuvant therapy proved effective for melanoma patients in a real-world setting, with a manageable toxicity profile. Toxicity frequencies were low leading to low incidence of unscheduled medical visits, tests, and treatment discontinuations.

وصف الملف: 10 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1097/CMR.0000000000000888Test; Melanoma Research, 2023, vol. 33, num. 5, p. 388-397; https://doi.org/10.1097/CMR.0000000000000888Test; http://hdl.handle.net/2445/205363Test

الإتاحة: https://doi.org/10.1097/CMR.0000000000000888Test
http://hdl.handle.net/2445/205363Test

المؤلفون: Piñero-Madrona, Antonio, Cerezuela-Fuentes, Pablo, Ruiz-Merino, Guadalupe, Martínez-Barba, Enrique, Ortiz-Reina, Sebastián, Martínez-Ortiz, María José, López-Ávila, Angel, Frías-Iniesta, José F., Viney, Alice, Cabezas-Herrera, Juan

المساهمون: Universidad de Murcia

المصدر: Archives of Dermatological Research ; volume 315, issue 7, page 1971-1978 ; ISSN 1432-069X

مصطلحات موضوعية: Dermatology, General Medicine

الوصف: The anatomical location of cutaneous melanoma is a relevant independent prognostic factor in melanoma. The aim of the study is to know the prognosis of lower limb cutaneous melanoma related to their location within the limb, regardless of the histological type, and if there are any other influencing variables. A real-world data observational study was developed. The lesions were divided depending on the location of the melanoma (thigh, leg and foot). Bivariate and multivariate analysis were performed, and melanoma-specific survival and disease-free survival rates were calculated. When these analysis were done, the results showed that, in melanomas of the lower limb, location on the foot presented a lower melanoma-specific survival rate compared to more proximal locations, and only the anatomical location presents statistical significance to discriminate cases with a higher mortality risk and a lower disease-free survival rate among distal melanomas (mainly on the foot). In conclusion, this study confirms that a more distal location of lower limb cutaneous melanoma is a relevant prognostic factor. Trial registration number NCT04625491 retrospectively registered.

الإتاحة: https://doi.org/10.1007/s00403-023-02571-zTest

المؤلفون: Rodas, Iván Márquez, Saiag, Philippe, Merino, Luis de la Cruz, Dutriaux, Caroline, Rodríguez-Moreno, Juan, Robert, Caroline, Arance, Ana, Álvarez, Eduardo Castañón, Cerezuela-Fuentes, Pablo, Montaudie, Henry, Sanmamed, Miguel, Cao, María González, Charles, Julie, López Criado, María Pilar, Berrocal, Alfonso, Miguel, Enrique de, Funk-Brentano, Elisa, Prey, Sorilla, Huertas, Roberto, Abreu, Delvys Rodríguez, Couselo, Eva Muñoz, Martin-Liberal, Juan, López, Javier Sánchez, Escuin-Ordinas, Helena, Quintero, Marisol, Maciá, Sonia, Chaney, Marya, Dalle, Stephane

المصدر: Late-Breaking Abstracts

الإتاحة: https://doi.org/10.1136/jitc-2021-sitc2021.961Test

المؤلفون: Cerezuela Fuentes, Pablo

مرشدي الرسالة: Piñero Madrona, Antonio, Trujillo Santos, Antonio Javier, Facultades, Departamentos, Servicios y Escuelas::Facultades de la UMU::Facultad de Medicina

مصطلحات موضوعية: Melanoma, CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología

الوصف: El melanoma es la neoplasia maligna cuya incidencia aumenta más rápidamente en el mundo. Hasta un 15-20% de los pacientes con melanoma en estadio inicial desarrollarán metástasis ganglionares. En la situación de adyuvancia, el principal cambio referido a la estadificación surgió en los 90 con la descripción (Morton et al) de la técnica de la biopsia selectiva del ganglio centinela (BSGC). Su principio consiste en la detección, exéresis y análisis anatomopatológico del primer ganglio al que drenarían las células tumorales; la ausencia de éstas, aseguraría en gran medida, la ausencia de diseminación de la enfermedad, evitando así linfadenectomías y su morbilidad. Actualmente la BSGC ha demostrado ser factor pronóstico correlacionándose su realización con la supervivencia libre de enfermedad en pacientes con melanomas finos y de grosor intermedio. En España actualmente el único tratamiento adyuvante aceptado en melanoma es el interferón alfa 2b, en esquema de altas dosis y en pacientes en estadio IIB o en estadio III (con afectación ganglionar), por lo que la positividad de la BSGC implica un cambio de estadio y, por tanto, de propuesta terapéutica. Si bien diversos estudios valoran el impacto de la BSGC sobre el pronóstico final de los pacientes, poco se sabe de cómo ha cambiado esta práctica en la estadificación de los pacientes y si esta modificación del estadio implica un cambio en la decisión en cuanto al tratamiento a realizar y al pronóstico final de los pacientes. Objetivos: se pretende determinar las variables que se relacionan con la realización de la BSGC en la práctica clínica en pacientes con melanoma cutáneo, conocer si la positividad de la BSGC determina que los pacientes sean tratados en adyuvancia con interferón, conocer si en los pacientes que reciben interferón debido al resultado de la BSGC se mejora el pronóstico con respecto a los pacientes que no reciben interferón tras la BSGC y definir las características de los pacientes que recaen y de las recaídas dependiendo de si se realiza o no la BSGC. Material y métodos: Se realizó un estudio observacional de cohortes, no intervencionista, con un diseño analítico longitudinal con carácter ambidireccional en la Sección de Oncología Médica del Hospital General Universitario Santa Lucía incluyendo en el análisis a los pacientes diagnosticados de melanoma en estadio inicial sin afectación clínica ganglionar. El primer caso incluido fue diagnosticado el 02/09/96 y el último el 24/09/15. Se analizaron las variables relacionadas con la realización de la BSGC, con el cambio de estadio y de propuesta de tratamiento, de pronóstico y las características de las recaídas. Conclusiones: En la serie presentada las variables que se relacionan con la realización de la BSGC en la práctica clínica en pacientes con melanoma cutáneo son la presencia de melanomas nodulares, de melanomas ulcerados, un índice de Breslow mayor o igual a 1, un índice de Clark III o IV y un número de mitosis ≥1/mm2. La realización de la BSGC determina que los pacientes sean tratados en adyuvancia con interferón en al menos un tercio de todos los pacientes que finalmente reciben interferón tras el diagnóstico inicial de melanoma. No es posible demostrar una mejoría del pronóstico en los pacientes que reciben tratamiento adyuvante con interferón con respecto a los pacientes que no lo reciben tras una biopsia selectiva del ganglio centinela positiva. No es posible encontrar diferencias ni en las características de los pacientes que recaen ni en las características de la recaída dependiendo de que se realice o no la BSGC. Introduction: Melanoma is the malignant neoplasm whose incidence increases most rapidly in the world. Up to 15-20% of patients with early-stage melanoma will develop nodal metastases. The main change related to staging on the adjuvant setting, arose in the 1990s, with the description by Morton et al about the technique of sentinel node biopsy (SNB). Its principle consists in the detection, resection and anatomopathological analysis of the first nodal to which the tumor cells would drain; The absence of these would ensure the absence of dissemination of the disease, thus avoiding lymphadenectomies and their morbidity. SNB is a prognostic factor correlating its achievement with disease-free survival in patients with thin and intermediate thickness melanomas. In Spain currently, the only accepted adjuvant treatment in melanoma is interferon alpha 2b, in a high-dose regimen and in patients with stage IIB or stage III (with nodal involvement), so that the positivity of SNB involves a change of stage and, therefore, a therapeutic proposal. Although several studies assess the impact of SNB on patients' final prognosis, little is known about how this practice has changed in patient staging and whether this change implies a modification in the treatment decision or the final prognosis of patients. Objectives: To determine the variables related to the performance of SNB in clinical practice in patients with cutaneous melanoma, to know if the positivity of SNB determines the adjuvant treatment with interferon, to know if the patients who receive interferon due to the SNB result improves the prognosis respect to patients who do not receive interferon after SNB, and define the characteristics of relapsing patients and of relapses depending on SNB was done or not. Material and methods: A non-interventional, observational cohort study with a longitudinal analytical design with an ambi-directional character was performed in the Sección de Oncología Médica del Hospital General Universitario Santa Lucía, of patients diagnosed with melanoma without affectation lymph node. The first case included was diagnosed on 02/09/96 and the last on 09/24/2015. We analyzed the variables related to the performance of the SNB, with the change of stage and treatment proposal, prognosis and characteristics of relapses. Conclusions: In this series, variables related to the performance of SNB in clinical practice in patients with cutaneous melanoma are the presence of nodular or ulcerated melanomas, a Breslow index ≥1, an index of Clark III or IV and a number of mitosis ≥1/mm2. The completion of the SNB determines that patients are treated in the adjuvant setting with interferon in at least one-third of all patients who finally receive interferon after the initial diagnosis of melanoma. It is not possible to demonstrate an improvement in prognosis in patients receiving adjuvant interferon therapy with respect to patients who do not receive it following a positive sentinel node biopsy. It is not possible to find differences in the characteristics of the relapsed patients or in the characteristics relapse depending on whether the SNB is done or not.

الوصول الحر: http://hdl.handle.net/10201/55939Test

المؤلفون: Lopez-Martin, Jose A., Arance Fernández, Ana, Ríos-Martín, Juan José, Hernández-Losa, Javier, Alós Hernández, Lucía, Cerezuela Fuentes, Pablo, Ortiz Reina, Sebastián, Ortega Izquierdo, Maria Eugenia, Martí Laborda, Rosa Ma., Soberino García, Jesús, Ferrer Fábrega, Berta, Rodríguez-Peralto, José L., ABSOLUT-BRAF Study Group

مصطلحات موضوعية: Melanoma

الوصف: Real-world data on BRAF mutation frequency in advanced melanoma are lacking in Spain. Moreover, data available on clinicopathological profile of patients with advanced BRAF-mutant melanoma are currently limited. This study aimed to assess the frequency of BRAF V600 mutations in Spanish patients with advanced or metastatic melanoma and to identify clinical and histopathological features associated with BRAF-mutated tumors. A multicenter, cross-sectional epidemiological study was conducted in 33 Spanish hospitals in adult patients with stage IIIc/IV melanoma. A total of 264 patients were included. The median age was 68 years and 57% were male. Melanoma mainly involved skin with intermittent (40.4%) and low or no sun exposure (43.5%). Most patients (85.6%) had stage IV disease (M1a: 19.3%; M1b: 13.3%; M1c: 22.7%). Serum lactate dehydrogenase levels were elevated in 20% of patients. Superficial spreading melanoma was the most frequent histological type (29.9%). Samples were predominantly obtained from metastases (62.7%), mostly from skin and soft tissues (80%). BRAF mutation analysis was primarily performed using the Cobas 4800 BRAF V600 Mutation Test (92.8%) on formalin-fixed, paraffin-embedded tissue (95.8%). BRAF mutations were detected in 41.3% of samples. Multivariate analysis identified age (odd ratio [OR] 0.975) and stage IV M1a (OR 2.716) as independent factors associated with BRAF mutation. The frequency of BRAF mutations in tumor samples from patients with advanced or metastatic melanoma in Spain was 41.3%. BRAF mutations seem to be more frequent in younger patients and stage M1a patients. This study provides the basis for further investigation regarding BRAF-mutated advanced melanoma in larger cohorts. ; This study was sponsored by Roche Farma S.A.

وصف الملف: application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1016/j.tranon.2020.100750Test; Translational Oncology, 2020, vol. 13, núm. 6, p. 10075; http://hdl.handle.net/10459.1/70145Test; https://doi.org/10.1016/j.tranon.2020.100750Test

الإتاحة: https://doi.org/10.1016/j.tranon.2020.100750Test
http://hdl.handle.net/10459.1/70145Test

المؤلفون: Ochenduszko, Sebastian, García Sanchez, Javier, Fita, María José Juan, González‐Barrallo, Inés, Herrero Colomina, Julio, Mujika, Karmele, Beveridge, Roberto Diaz, Martínez, Silverio Ros, Lafuente, Blanca Sánchez, Tomas, Alberto Cunquero, Jaime, Alfonso Berrocal, Cerezuela Fuentes, Pablo, Fra, Pablo Luna, Peeters, Alicia Gervás, Meana García, José Andrés, García, María Asunción Algarra, Altozano, Javier Perez, Cancela, Maria, Puchades, Almudena Mateu, Roca, Francisco Ferrando

المصدر: Pigment Cell & Melanoma Research; Sep2023, Vol. 36 Issue 5, p388-398, 11p

مصطلحات موضوعية: MELANOMA, NEUTROPHIL lymphocyte ratio, COHORT analysis, POSITRON emission tomography computed tomography, SCIENTIFIC observation

مستخلص: Anti‐programmed death‐1 (anti‐PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real‐world study analyzed the feasibility of elective anti‐PD1 discontinuation in advanced melanoma patients with CR and evaluated factors related to sustained response. Thirty‐five patients with advanced cutaneous or primary unknown melanoma with CR to nivolumab or pembrolizumab from 11 centers were included. Mean age was 66.5 years, and 97.1% had ECOG PS 0–1. 28.6% had ≥3 metastatic sites with 58.8% having M1a‐M1b disease; 8.6% had liver and 5.7% had brain metastases. At baseline, 80% had normal LDH, and 85.7% had a neutrophil‐to‐lymphocyte ratio ≤3. 74.3% of patients had CR confirmed in PET‐CT. Median duration of anti‐PD1 was 23.4 months (range 1.3–50.5). 24 months after therapy discontinuation, 91.9% of patients were progression‐free. Estimated PFS and OS at 36, 48, and 60 months from the start of anti‐PD1 were 94.2%, 89.9%, 84.3%, and 97.1%, 93.3%, 93.3%, respectively. Antibiotics use after anti‐PD1 discontinuation increased the odds of progression (OR 16.53 [95% CI 1.7, 226.03]). The study confirms the feasibility of elective anti‐PD1 discontinuation in advanced melanoma patients with CR and favorable prognostic factors at baseline. [ABSTRACT FROM AUTHOR]

: Copyright of Pigment Cell & Melanoma Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: García de Guadiana-Romualdo, Luis, Cerezuela-Fuentes, Pablo, Español-Morales, Ignacio, Esteban-Torrella, Patricia, Jiménez-Santos, Enrique, Hernando-Holgado, Ana, Albaladejo-Otón, María Dolores

المصدر: Biochemia Medica ; ISSN 1330-0962 (Print) ; ISSN 1846-7482 (Online) ; Volume 29 ; Issue 1

مصطلحات موضوعية: febrile neutropenia, prognosis, Multinational Association for Supportive Care in Cancer, procalcitonin, lipopolysaccharide binding protein

الوصف: Introduction: Cancer patients with chemotherapy-induced febrile neutropenia are a heterogeneous group with a significant risk of serious medical complications. In these patients, the Multinational Association for Supportive Care in Cancer (MASCC) score is the most widely used tool for risk-stratification. The aim of this prospective study was to analyse the value of procalcitonin (PCT) and lipopolysaccharide binding protein (LBP) to predict serious complications and bacteraemia in cancer patients with febrile neutropenia, compared with MASCC score. Materials and methods: Data were collected from 111 episodes of febrile neutropenia admitted consecutively to the emergency department. In all of them, MASCC score was calculated and serum samples were collected for measurement of PCT and LBP by well-established methods. The main and secondary outcomes were the development of serious complications and bacteraemia, respectively. Results: A serious complication occurred in 20 (18%) episodes and in 16 (14%) bacteraemia was detected. Areas under the receiver operating characteristic curve (ROC AUC) of MASCC score, PCT and LBP to select low-risk patients were 0.83 (95% confidence interval (CI): 0.74 - 0.89), 0.85 (95% CI: 0.77 - 0.91) and 0.70 (95% CI: 0.61 - 0.78), respectively. For bacteraemia, MASCC score, PCT and LBP showed ROC AUCs of 0.74 (95% CI: 0.64 - 0.82), 0.86 (95% CI: 0.78 - 0.92) and 0.76 (95% CI: 0.67 - 0.83), respectively. Conclusion: A single measurement of PCT performs similarly as MASCC score to predict serious medical complications in cancer patients with febrile neutropenia and can be a useful tool for risk stratification. Besides, low PCT concentrations can be used to rule-out the presence of bacteraemia.

وصف الملف: application/pdf

العلاقة: https://hrcak.srce.hr/213856Test

الإتاحة: https://doi.org/10.11613/BM.2019.010702Test
https://hrcak.srce.hr/213856Test
https://hrcak.srce.hr/file/312559Test

المؤلفون: Piñero-Madrona, Antonio, Goméz-Ruiz, Alvaro Jesús, Ruiz-Merino, Guadalupe, Martínez-Barba, Enrique, Cerezuela-Fuentes, Pablo, Rodríguez-López, José Neptuno, Cabezas-Herrera, Juan

المساهمون: Ministerio de Economía y Competitividad, Fundación Séneca, the Región de Murcia

المصدر: Journal of the American Academy of Dermatology ; volume 80, issue 3, page 806-808 ; ISSN 0190-9622

مصطلحات موضوعية: Dermatology

الإتاحة: https://doi.org/10.1016/j.jaad.2018.09.034Test
https://api.elsevier.com/content/article/PII:S0190962218326446?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0190962218326446?httpAccept=text/plainTest

المؤلفون: Gonzalez-Cao, Maria, Puertolas, Teresa, Martinez-Vila, Clara, Carrera, Cristina, Maldonado Seral, Cayetana, Rodríguez-Jiménez, Pedro, Sequero, Silvia, Cerezuela-Fuentes, Pablo, Feltes Ochoa, Rosa, Muñoz, Eva, Antoñanzas Basa, Mónica, Martín-Liberal, Juan, Soria, Ainara, Francisco Rodriguez Moreno, Juan, Marquez-Rodas, Ivan, Lopez Criado, Pilar, Luis Manzano, José, Lopez-Castro, Rafael, Ayala de Miguel, Pablo, Villalobos, Laura

المصدر: Clinical & Translational Oncology; Mar2023, Vol. 25 Issue 3, p768-775, 8p

مستخلص: Background: The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ("GRAVID"). Methods: The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021. Results: One hundred-fifty cases were registered. Median age was 68 years (range 6–95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February–May 2020, August–November 2020, and December 2020–April 2021. The first wave had the highest number of registered cases and COVID-19 mortality. Conclusion: Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection. Clinicaltrials.gov identifier: NCT04344002. [ABSTRACT FROM AUTHOR]

: Copyright of Clinical & Translational Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Gonzalez-Cao, Maria, Puertolas, Teresa, Martinez-Vila, Clara, Carrera, Cristina, Maldonado Seral, Cayetana, Rodríguez-Jiménez, Pedro, Sequero, Silvia, Cerezuela-Fuentes, Pablo, Feltes Ochoa, Rosa, Muñoz, Eva, Antoñanzas Basa, Mónica, Martín-Liberal, Juan, Soria, Ainara, Francisco Rodriguez Moreno, Juan, Marquez-Rodas, Ivan, Lopez Criado, Pilar, Luis Manzano, José, Lopez-Castro, Rafael, Ayala de Miguel, Pablo, Villalobos, Laura, Martin Algarra, Salvador, Gonzalez-Barrallo, Ines, Boada, Aram, García Castaño, Almudena, Puig, Susana, Crespo, Guillermo, Luna Fra, Pablo, Aguayo Zamora, Cristina, Feito Rodríguez, Marta, Valles, Lara, Drozdowskyj, Ana, Gardeazabal, Jesús, Antonio Fernandez-Morales, Luis, Rodrigo, Alberto, Cruz, Raquel, Yelamos, Oriol, Rubio, Belen, Mujica, Karmele, Provencio, Mariano, Berrocal, Alfonso

المساهمون: Novartis Pharma

المصدر: Clinical and Translational Oncology ; volume 25, issue 3, page 768-775 ; ISSN 1699-3055

مصطلحات موضوعية: Cancer Research, Oncology, General Medicine

الإتاحة: https://doi.org/10.1007/s12094-022-02985-7Test